Plastic container comprising cyclic polyolefin layer

Abstract

The present invention provides and a plastic container and multilayered films, which comprises a heat-sealable seal layer, a cyclic polyolefin layer, and an outermost layer, wherein the seal layer comprises polypropylene, the cyclic polyolefin layer comprises a cyclic polyolefin polymer or a cyclic polyolefin copolymer, and the outermost layer comprises a layer containing polypropylene, and which further comprises a resin composition layer comprises a blended product of a propylene polymer and a styrene elastomer. The plastic container of the present invention can suppresses a reduction in the medicament content of a liquid-state medicament and is excellent in terms of shock resistance, handling ability during the filling of the container with the medicament, and the moldability and transparency of the container.

1 - 19 . (canceled) 
     
     
         20 . A pharmaceutical formulation in a unit dosage form comprising 3-methyl-1-phenyl-2-pyrazolin-5-one;
 wherein the unit dosage form is a solution stored in a plastic container, and   wherein the container comprises:
 a multilayered film having six or more layers, wherein the six or more layers are:
 an innermost heat-sealable seal layer consisting essentially of polypropylene, 
 a first resin composition layer disposed on the innermost heat-sealable seal layer consisting essentially of a resin composition comprising a blended product of a propylene polymer and a styrene elastomer, 
 a cyclic polyolefin barrier layer disposed on the first resin composition layer consisting of a polymer consisting of repeating units represented by the formula (1) and repeating units represented by the formula (1′): 
 
   
       
         
           
           
               
               
           
         
         
           
             
               wherein each of Ra, Ra′, Rb and Rb′, identically or differently, represents a hydrogen, a hydrocarbon residue, a halogen, an ester, a nitrile or a pyridyl; or Ra and Rb may bind to one another to form a ring; or Ra′ and Rb′ may bind to one another to form a ring; each of m and m′ represents an integer of 1 or greater; and each of n and n′ represents an integer of 0 or 1 or greater, 
             
             two or more additional resin composition layers disposed on the cyclic polyolefin barrier layer consisting essentially of a resin composition comprising a blended product of a propylene polymer and a styrene elastomer, 
             and 
             an outermost layer disposed on the additional resin composition layers consisting essentially of a polypropylene layer; 
           
           wherein the plastic container is molded by heat sealing peripheral portions of the multilayered films. 
         
       
     
     
         21 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the cyclic polyolefin barrier layer has a glass transition temperature (Tg) of 80° C. to 120° C. 
     
     
         22 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the melt flow rate (230° C., 21.2 N) value of the cyclic polyolefin barrier layer is 1 to 20 (g/10 minutes). 
     
     
         23 . The pharmaceutical formulation in a unit dosage form according to  claim 22 , wherein the melt flow rate (230° C., 21.2 N) value of the seal layer and/or the outermost layer is 1 to 4 (g/10 minutes). 
     
     
         24 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the maximum fusion peak temperature of the seal layer is 125° C. to 135° C. 
     
     
         25 . The pharmaceutical formulation in a unit dosage form according to  claim 24 , wherein the highest fusion peak temperature of the seal layer is 150° C. to 160° C. 
     
     
         26 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the fusion peak temperature of the outermost layer is 160° C. to 170° C. 
     
     
         27 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the plastic container can be sterilized at 115° C. for 30 minutes or more. 
     
     
         28 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the plastic container can be sterilized at 121° C. for 15 minutes or more. 
     
     
         29 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the plastic container is in the form of an infusion bag. 
     
     
         30 . The pharmaceutical formulation in a unit dosage form according to  claim 29 , wherein the plastic container can be sterilized at 115° C. for 30 minutes or more. 
     
     
         31 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the unit dosage form comprises 30 mg of 3-methyl-1-phenyl-2-pyrazolin-5-one. 
     
     
         32 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the 3-methyl-1-phenyl-2-pyrazolin-5-one is contained in a concentration of 0.06 mg/mL or higher to 2 mg/mL or lower. 
     
     
         33 . The pharmaceutical formulation in a unit dosage form according to  claim 32 , wherein the 3-methyl-1-phenyl-2-pyrazolin-5-one is contained in a concentration of 0.1 mg/mL or higher to 0.6 mg/mL or lower. 
     
     
         34 . The pharmaceutical formulation in a unit dosage form according to  claim 33 , wherein the 3-methyl-1-phenyl-2-pyrazolin-5-one is contained in a concentration of about 0.3 mg/mL. 
     
     
         35 . The pharmaceutical formulation in a unit dosage form according to  claim 20 , wherein the 3-methyl-1-phenyl-2-pyrazolin-5-one is contained in an injection solution. 
     
     
         36 . The pharmaceutical formulation in a unit dosage form according to  claim 35 , wherein the injection solution is saline.